Plain-English translation of NCT05960721 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
People with atrial fibrillation (an irregular heartbeat) have a high risk of stroke because blood clots can form in a part of the heart called the left atrial appendage. Many patients receive a small device to seal off this area and prevent clots from escaping. This trial is testing whether taking rivaroxaban, a blood thinner medication, after this device placement can further reduce stroke risk compared to the current standard treatment approach.
Even after the device is placed, some patients still have strokes from other sources in the heart. Doctors want to know whether adding this medication to the standard care can provide extra protection and reduce stroke risk even further.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to take either the new medication approach or the standard guideline-recommended treatment. Depending on your bleeding risk score, you would take different doses of medication for the first 3 months, then switch to a long-term maintenance dose. You would need to take your assigned medication daily and attend follow-up visits to monitor your health and check for any side effects. The study involves about 4,220 participants across multiple hospitals.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China